ABSTRACT Menaquinone (MK) in bacterial membrane is an attractive target for the development of novel therapeutic agents. Mining the untapped chemical diversity encoded by Gram-negative

bacteria presents an opportunity to identify additional MK-binding antibiotics (MBAs). By MK-binding motif searching of bioinformatically predicted linear non-ribosomal peptides from 14,298

sequenced genomes of 45 underexplored Gram-negative bacterial genera, here we identify a novel MBA structural family, including silvmeb and pseudomeb, using structure prediction-guided

chemical synthesis. Both MBAs show rapid bacteriolysis by MK-dependent membrane depolarization to achieve their potent activities against a panel of Gram-positive pathogens. Furthermore,

strategy for discovering novel biomedically relevant agents to confront the crisis of antimicrobial resistance. SIMILAR CONTENT BEING VIEWED BY OTHERS IDENTIFICATION OF STRUCTURALLY DIVERSE

MENAQUINONE-BINDING ANTIBIOTICS WITH IN VIVO ACTIVITY AGAINST MULTIDRUG-RESISTANT PATHOGENS Article 23 December 2021 SYNTHESIS OF MACROCYCLIC NUCLEOSIDE ANTIBACTERIALS AND THEIR INTERACTIONS

WITH MRAY Article Open access 20 December 2022 AN AMPHIPATHIC PEPTIDE WITH ANTIBIOTIC ACTIVITY AGAINST MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA Article Open access 23 June 2020

INTRODUCTION Antimicrobial resistance infections present a growing public healthcare problem1,2. Novel antibiotics whose modes of action (MOAs) are distinct from those of clinically used

drugs, are urgently needed to combat antibiotic-resistant pathogens3,4,5. Menaquinone (MK), as the electron acceptor in the bacterial membrane, is essential to the normal electrical

transport in the majority of Gram-positive pathogens6. Interestingly, human cells could not produce MK, making it an appealing molecular target for the development of mechanistically novel

antibiotics to circumvent existing resistance mechanisms7,8. Previously, three closely cyclic lipodepsipeptides, including lysocin E, WAP-8294A2, and WBP-29479A1, have been identified to

bind directly to MK, thus resulting in rapid lysis of multidrug-resistant (MDR) Gram-positive pathogens9,10,11,12. Particularly, WAP-8294A2 has been progressed to phase I clinical trials,

indicating that menaquinone-binding antibiotics (MBAs) exhibit great potential for the development of novel anti-infective small molecule drugs13. Two years ago, we combined two

(meta)genomic mining approaches to identify a few novel MBAs that could rapidly kill methicillin-resistant _Streptococcus aureus_ (MRSA) and MDR _Mycobacterium tuberculosis_14.

Interestingly, we found that although MBAs are a kind of structurally diverse cyclic lipodepsipeptides, a conserved MK-binding motif (GXLXXXW) in MBAs was identified14. Particularly,

considering most sequenced BGCs are not or lowly expressed in laboratory fermentation studies, a synthetic bioinformatic natural product (synBNP) method instead of the traditional

fermentation strategy was used to rapidly access MBAs on a large scale14. The synBNP method could be done by firstly bioinformatically predicting the encoded structure inspired by the

primary sequence of a BGC and then chemically synthesizing the predicted structure15,16,17. To facilitate the successful therapeutic development of this mechanistically interesting class of

antibiotics, additional chemical entities of MBAs with novel structures should be further explored from untapped microbial sources. In this study, we accessed 14,298 genomes of 45

underexplored Gram-negative bacterial genera by combining the motif search-guided large-scale genome mining with the synBNP method, and successfully identified a novel MBA structural family

with potent in vivo anti-MRSA activity. RESULTS IDENTIFICATION OF POTENTIAL MBA BGCS FROM UNDEREXPLORED GRAM-NEGATIVE BACTERIA To discover more novel MBAs, we first summarized the sources of

all identified MBA BGCs. Besides the three known MBA BGCs (MBAs 1–3) are from soil microbiomes, the other known MBA BGCs (i.e., Lysocin E and WBP-29479A1) are from underexplored

Gram-negative bacterial genera, including _Dyella_, _Lysobacter_ and _Paracoccus_ (Table S1)9,10,12,14. These results suggest that Gram-negative bacteria are rich underexplored sources of

MBA BGCs, which should be further exploited. Previously, we developed a general approach by motif searching a bioinformatically predicted database of natural products (i.e., non-ribosomal

peptides) to identify BGCs that encode molecules with specific desired features14. Using the motif search-guided chemical synthesis approach, we rapidly identified three MBAs (MBAs 4-6)

inspired by primary sequences from ~10,000 Gram-positive and Gram-negative bacterial genomes downloaded from the antiSMASH database14. To discover more MBAs with novel structural families,

in this study, we systematically collected 14,298 genomes from 45 underexplored Gram-negative bacterial genera, which belong to five phyla, including Bacteroidetes, Chloroflexi, Firmicutes,

Tectomicrobia, and Proteobacteria18,19,20. Furthermore, BGCs from these genomes were analyzed by the antiSMASH pipeline, and the A-domain substrate binding pockets from NRPS BGCs were

compared to a manually curated list of A-domain signature sequences from characterized BGCs that we developed previously14,21. Based on A-domain substrate prediction, we generated a database

of linear predicted peptides that contains 2818 NRPs with at least five building blocks (Fig. 1a)22. To decrease the noise when motif searching, we manually deleted the predicted peptides

encoded by the known MBA BGCs in our developed predicted NRP database (G− version). Then, considering that these NRPS BGCs are often truncated in assembled genomes using short-read sequence

data, we used the full MK-binding motif (GXLXXXW) as well as its two partial motifs (GXL and LXXXW) to search our database. For the full motif search, we identified a novel BGC from the

genome of _Eleftheria terrae_ P9846-PB, suggesting that it might encode a potential MBA (Fig. 1a)23. By further bioinformatic analysis, as shown in Fig. S1, the newly identified BGC is

likely to encode the known MBA, MBA114. For the partial motif search, LXXXW was only found in the potential MBA1 BGC from _E. terrae_ P9846-PB. Notably, besides the above potential MBA1 BGC

in the GXL motif search, we identified two truncated BGCs from _Dyella silvatica_ GDMCC 1.1900 and _Lysobacter capsici_ NF87-2, whose encoded peptides shared partial amino acids with known

MBAs (Fig. 1a)24. To access the complete peptide sequence encoded by the partial MBA7 BGC from _D. silvatica_ GDMCC 1.1900, we re-sequenced the complete genome of this strain (Fig. 1b). The

A-domain analysis of re-sequenced MBA7 BGC predicted it would encode the MK-binding motif GXLXXXW containing peptides that might represent MBA (Fig. S2 and Table S2). On the other side,

considering the strain _L. capsici_ NF87-2 is unavailable, we tried to identify similar BGCs to the potential MBA8 BGC from _L. capsici_ NF87-2 in the GenBank database. Fortunately, a new

NRP BGC from _Pseudomonas_ sp. CGJS7 was found to be likely to encode the potential MBA8 (Figs. 1b, S3, 4 and Tables S3, 4). Our findings suggest that MBA BGCs were from more diverse genera

of Gram-negative bacteria, including _Eleftheria_ and _Pseudomonas_, besides the three above genera _Dyella_, _Lysobacter_, and _Paracoccus_. Notably, all three genera described above are

from Alphaproteobacteria or Gammaproteobacteria, but _Eleftheria_ is a rare genus of Betaproteobacteria that have not traditionally been part of microbial natural product discovery programs

(Table S1)18. The genus _Eleftheria_ was only first described in 2015, and until now, _E. terrae_ P9846-PB is the only identified strain in this genus23. Finally, we aligned the known MBA

peptide sequences and the two novel peptides predicted by the potential MBA7 and MBA8 BGCs to generate a phylogenetic tree. As shown in Fig. 2a. the MBA7 and MBA8 BGCs-predicted peptides

formed a distinct clade, which suggests that their products are likely to make up a novel MBA structural family. STRUCTURAL PREDICTION AND CHEMICAL SYNTHESIS OF MBA7 AND MBA8 BGC PRODUCTS

With the increasing accuracy of bioinformatic algorithms for predicting natural product (i.e., non-ribosomal peptides) structures, total chemical synthesis (i.e., solid-phase peptides

synthesis (SPPS)) of the bioinformatically predicted BGC product (that is, a synthetic bioinformatic natural product (synBNP)) provides an alternative and potentially more straightforward

means for accessing small molecules encoded by completely sequenced BGCs14,15,16,17. The structural prediction-guided chemical synthesis strategy not only overcomes a lack of BGC expression

but also skips the time-consuming process of isolating and structurally characterizing compounds from microbial fermentation broths14,15,16,17. Indeed, we tried to culture the strain _D.

silvatica_ GDMCC 1.1900 in three different liquid media but failed to detect the MBA7 BGC-encoded products. As shown in the Figs. S2–4, the MBA7 and MBA8 BGCs consist of two large NRPS genes

in which a condensation starter domain encoded by the first NRPS gene is predicted to initiate NRPS biosynthesis with a fatty acid, such as _R_-3-hydroxy-octanoic acid found in the two

known MBAs (lysocins and WAP-8294A)9,10. Distinct from many other cyclic lipodepsipeptides25, changes in the fatty acid tail of known MBAs did not result in substantial differences in

antimicrobial activity9,10. Therefore, based on A-domain substrate specificity analysis (Tables S2–4), the unmodified linear lipopeptide predicted by each NRPS gene was used to be the direct

precursor to the bioactive cyclic lipopeptide encoded by the MBA7 or MBA8 BGCs22. The commercially available _R_-3-hydroxy-octanoic acid was used in the synthesis of the predicted

lipopeptides encoded by both MBA7 and MBA8 BGCs. Noteworthy, because the first amino acid was predicted to contain a nucleophilic side chain (Ser), the _R_-3-hydroxy-octanoic acid

derivatized linear peptide can either be cyclized through the β-hydroxyl group of the fatty acid (cyclized through fatty acid, cFA) or through a nucleophilic amino acid side chain (cyclized

through side chain, cSC). Finally, we generated four syn-BNPs for antimicrobial bioactivity screening, including MBA7-cFA, MBA7-cSC, MBA8-cFA and MBA8-cSC (Figs. 2b and S5, 6). The

identities of the four syn-BNPs that encode potential MBAs were then confirmed by HPLC and high-resolution MS (Figs. S7–10 and Table S5). ANTIMICROBIAL SPECTRUM OF SYNTHESIZED MBA7 AND MBA8

BGC PRODUCTS MBAs have been proven to have antibacterial activity against diverse Gram-positive bacteria, including _Bacillus_, _Micrococcus_, _Mycobacterium_, and _Staphylococcus_ spp.

because the electrical transport of these strains relies on MK9−14. To determine whether the four above differentially cyclized structures (MBA7-cFA, MBA7-cSC, MBA8-cFA, and MBA8-cSC) from

single linear peptides have antibacterial activity, we initially tested them against a panel of Gram-positive bacteria (_Bacillus subtilis_, _Micrococcus luteus_, _Mycobacterium smegmatis_,

and _Staphylococcus aureus_). We found that only MBA7-cFA or MBA8-cFA with cyclization through the 3-hydroxy of the _N_-terminal fatty acid showed potent antibiotic activities against all

six tested strains (Fig. 2c, d). MBA7-cSC or MBA8-cSC with cyclization through the serine at the first position lost antibacterial activities. Therefore, we speculate that MBA7-cFA and

MBA8-cFA are likely the products of the MBA7 and MBA8 BGCs, respectively. Then, we systematically tested the antimicrobial activities of MBA7-cFA and MBA8-cFA against a series of

Gram-positive, Gram-negative, and fungi. As shown in Table 1, both MBA7-cFA and MBA8-cFA were broadly active against the tested Gram-positive bacteria besides the three MK-deficient

_Enterococcus_ or _Staphylococcus_ spp. strains26,27. The similar antibacterial spectra against MK-producing and MK-deficient Gram-positive bacteria were also observed for the known MBAs14.

The MBA7-cFA and MBA8-cFA MICs ranged from 4 to 8 μg/mL against a panel of _S. aureus_ strains, including methicillin-resistant _S. aureus_ USA300 and penicillin-resistant _S. aureus_ ATCC

6538. Even at the highest concentration we tested (64 μg/mL), MBA7-cFA or MBA8-cFA did not show cytotoxicity to the two human cell lines, including HeLa and H295R (Table 1). Collectively,

the spectra of bioactivity data provided our first evidence that MBA7-cFA and MBA8-cFA were likely MBAs, which were renamed as silvmeb (_Dyella_ _silv__atica_ menaquinone-binding antibiotic)

and pseudomeb (_Pseudo__monas_ sp. CGJS7 menaquinone-binding antibiotic), respectively. The structures of silvmeb and pseudomeb were further confirmed using one- and two-dimensional nuclear

magnetic resonance (NMR) data (Figs. S11–22 and Tables S6, 7). MODE OF ACTION STUDIES OF SILVMEB AND PSEUDOMEB According to previous studies, the known MBAs could cause rapid bacteriolysis

due to MK-dependent membrane depolarization9,14. Therefore, we first evaluated silvmeb and pseudomeb for their abilities to lyse _S. aureus_ USA300. 4x the MIC of silvmeb or pseudomeb

antibiotics were added to _S. aureus_ cultures and vancomycin was used as the negative control. As shown in Fig. 3a, silvmeb or pseudomeb caused a significant and rapid decrease in the

number of viable bacterial cells. Furthermore, the 3,3′-dipropylthiadicarboncyanine iodide [DiSC3(5)] fluorescence assay was used to confirm that both silvmeb and pseudomeb could cause

membrane depolarization of _S. aureus_ (Fig. 3b). Then, to examine the relevance of MK to the antibacterial activities of silvmeb and pseudomeb, the MK feeding assay was performed for its

ability to suppress the antibacterial activity of silvmeb or pseudomeb. We found that, different from the negative control vancomycin, the MICs of silvmeb or pseudomeb against _S. aureus_

increased in a dose-dependent manner when MK was added to the assay medium. Ubiquinone (UQ), a related structure of MK, had no effect on the antibiotic activity of silvmeb or pseudomeb (Fig.

 3c). Meanwhile, we also tried to raise _S. aureus_ mutants when adding 4x the MICs of silvmeb or pseudomeb to the solid LB medium. Two and one resistant mutants were obtained for silvmeb

and pseudomeb at a frequency of 2.90 × 10−6 and 1.45 × 10−6, respectively (Fig. 3d). We further sequenced the genomes of the three mutants as well as the wild-type strain. For the

silvmeb-generated mutant S1, there was a point mutation in the MK biosynthesis gene _menH_, in which a stop code inside this gene was generated. For the silvmeb-generated mutant S2, there

was an in-frame deletion in the MK biosynthesis gene _menA_. For the pseudomeb-generated mutant P1, there was a missense variant in the MK biosynthesis gene _aroC_. There were no other point

mutations in all three mutants. In all cases, the MICs of silvmeb or pseudomeb against the two mutants were more than 64 μg/mL compared to against the wild type with 4 μg/mL (Fig. 3d).

Collectively, these results suggest that both silvmeb and pseudomeb are a kind of MBAs and could cause rapid lysis of _S. aureus_ USA300 cells by MK-dependent membrane depolarization.

ACTIVITY OF SILVMEB AND PSEUDOMEB IN A MURINE PERITONITIS-SEPSIS MODEL The in vivo efficacy of silvmeb and pseudomeb against multidrug-resistant _S. aureus_ was further examined in a mouse

peritonitis-sepsis model using vancomycin as the positive control (Fig. 4a). We found that, compared to the treatment of a methicillin-resistant _S. aureus_ USA300 strain infection with

vehicle alone (30% solutol), treatment with silvmeb or pseudomeb (10, 25, and 50 mg/kg) the mortality of significantly decreased infected ICR mice. A minimal dose of 25 mg/kg for silvmeb or

pseudomeb was required for 100% mice survival (Fig. 4b, c). Therefore, our identified novel MBA family with a unique structural scaffold and mode of action, including silvmeb and pseudomeb,

could be a valuable drug lead for the development of therapeutics for treating multidrug-resistant _S. aureus_ infections. DISCUSSION In this study, we assessed the large chemical space of

underexplored Gram-negative bacteria using motif search of bioinformatically generated natural product structures for the discovery of novel MBA structural families based on our newly

developed database (G− version). This motif search-guided chemical synthesis approach represents an alternative general platform to screen sequenced BGCs for the potential production of

bioactive natural products with specific desired features, such as calcium-dependent antibiotics with calcium-binding motif and cationic antimicrobial peptides with at least two positively

charged amino acids28,29. Beyond the conserved minimal MK-binding sequence (GXLXXXW), both silvmeb and pseudomeb contain a distinct L-Pro-5 and three to four Asn residues (Fig. 2d). The

hydrophobic lipid tail and hydrophobic glycine and leucine residues seen in both silvmeb and pseudomeb are likely important for interacting with either the lipid biolayer or the hydrophobic

polyprenyl tail of MK in bacterial membranes. The L-Pro-5 was only found in the third MBA family (including MBA3 and MBA4), and proposed to introduce discrete conformations into cyclic

peptides, which was also observed for _N_-methylated amino acids30. Additionally, either silvmeb or pseudomeb contains at least five different building blocks from the known MBAs. These

structural features make silvmeb and pseudomeb become a unique and novel MBA structural family (Fig. 2a). Finally, both silvmeb and pseudomeb were proven to be effective at treating MRSA

infections in a murine peritonitis-sepsis model. In the next step, gram-scale synthesis of silvmeb or pseudomeb would be required for their preclinical studies. Considering both silvmeb and

pseudomeb are a kind of common cyclopeptide structures, their scale-up synthesis could be done by properly optimizing peptide synthesis and purification methods31,32. Our discovery of the

two above novel in vivo MRSA active MBAs suggests that MBAs are a kind of structurally diverse and still underexplored antimicrobial lipodepsipeptide class. Although our newly identified

MBAs in this study have similar anti-MRSA activity to these previously reported MBAs (i.e., lysocins and WAP-8294A) in vitro and in vivo9−12,14, we did not further compare their differences

in pharmacokinetics (PK) and pharmacodynamics (PD) properties. Nevertheless, both silvmeb and pseudomeb, as novel MBA chemical entities, provide more possibilities to facilitate the

successful therapeutic development of this mechanistically interesting class of antibiotics. Collectively, our findings suggest that MBAs show large chemical diversity, which would

significantly facilitate the druggability studies of this kind of cyclic lipopeptides. Identification of silvmeb and pseudomeb adds to the arsenal of NP-inspired structures that are

available to explore in the effort to develop novel MBA-based therapeutics. METHODS CHEMICAL REAGENTS, CONSUMABLES, AND INSTRUMENTS Reagents for solid-phase peptide synthesis (SPPS),

including DCM (dichloromethane), DIPEA (_N_,_N_-diisopropylethylamine), DMAP (4-dimethylaminopyridine), DMF (_N_,_N_-dimethylformamide), HATU (_O_-(7-azabenzotriazol-1-yl)-_N_,_N_,_N_,

_N_’-tetramethyluronium hexafluorophosphate), HFIP (hex-afluoroisopropanol), PyAOP ((7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate) and TFA (trifluoroacetic acid),

were purchased Shanghai Titan (Shanghai, CN). 2-chlorotrityl resin, standard _N_-Fmoc amino acid, and Fmoc-_N_-Me-Val-OH building blocks were purchased from GL Biochem (Shanghai, CN).

(_R_)-3-hydroxy-octanic acid was purchased from Wuxi AppTec (Chengdu, CN). All solvents used for chromatography were HPLC grade or higher. Type II mucin from the porcine stomach was

purchased from Shanghai Titan. The fluorescent dye DiSC3(5) (3,3′-dipropylthiadicarbocyanine Iodide) was purchased from RHAWN Chem (Shanghai, CN), and the assay results were recorded using a

Tecan Spark 10 M Multimode plate reader. Menaquinone-7 (MK) and ubiquinone-10 (UQ) were purchased from Beijing InnoChem (Beijing, China) and Bide Pharmatech (Shanghai, China), respectively.

For HPLC, solvent A = H2O (0.1% v/v formic acid) and solvent B = CH3CN (0.1% v/v formic acid). LC-MS data were acquired on an Agilent 1290 Series HPLC coupled to a 6546 Series QTOF mass

spectrometer, equipped with an XBridge Prep C18 130 Å column (4.6 × 150 mm, 4.6 µm). Peptide purification was performed using an Agilent 1260 Series HPLC with UV detection and equipped with

an XBridge Prep C18 130 Å column (10 × 150 mm, 5 μm). 1H, 13C, DEPT135°, COSY, HSQC, and HMBC NMR spectra were acquired on a Bruker Avance DMX 700 MHz spectrometer equipped with cryogenic

probes (Shanghai Jiao Tong University, Shanghai). All spectra were recorded at 25 °C in DMSO-_d_6. Chemical shift values are reported in parts in million (ppm) and referenced to residual

solvent signals: 2.50 ppm (1H) and 39.52 ppm (13C). CONSTRUCTION OF AN IN-HOUSE PREDICTED LINEAR NON-RIBOSOMAL PEPTIDE (P-NRP) DATABASE FROM UNDEREXPLORED GRAM-NEGATIVE (G−) BACTERIA14 The

GenBank files of 14,298 complete bacterial genome assemblies from 45 genera of underexplored Gram-negative bacteria were downloaded from GenBank. Then, the unique p-NRP database (G- Version)

was constructed that contains 2818 linear predicted NRPs with at least five building blocks. To identify potential MBA BGCs, the resulting p-NRP database was searched using the full GXLXXXW

MK-binding motif and two partial motifs: GXL and LXXXW. For the GXLXXXW motif search, a novel BGC was identified from _Eleftheria terrae_ P9846-PB, which encodes potential MBA1. For the GXL

motif search, the potential MBA7 and MBA8 BGCs were identified from _Dyella silvatica_ GDMCC 1.1900 and _Lysobacter capsici_ NF87-2, respectively. To access the complete peptide sequence

encoded by MBA7 BGC, we re-sequenced the genomes of _D. silvatica_ GDMCC 1.1900 using PacBio single-molecule long-read sequencing technology. The A-domain analysis of re-sequenced MBA7 BGC

predicted it would encode GXLXXXW containing peptide that might represent a novel MBA (Fig. S2). Because the strain _L. capsici_ NF87-2 is unavailable, we tried to identify similar BGCs to

the potential MBA8 BGC from _L. capsici_ NF87-2 in the GenBank database. Fortunately, a new NRP BGC from _Pseudomonas_ sp. CGJS7 was found to be likely to encode the potential MBA8 (Fig. 1).

SOLID-PHASE PEPTIDE SYNTHESIS MBA7-cFA, MBA7-cSC, MBA8-cFA, and MBA8-cSC were synthesized using standard Fmoc-based solid-phase peptide synthesis methods on 2-chlorotrityl chloride resin

using commercially available Fmoc-protected amino acids14. Peptide synthesis started from the Leu building block at the sixth position of MBA7-cFA or MBA8-cFA, which was loaded on

2-cholorotrityl resin (0.3 g, 0.552 mmol/g) and was swollen in DCM for 20 min, drained as well as washed with DMF (3 mL, 3x). Peptide synthesis started from the Arg or Asn building block at

the ninth position of MBA7-cSC or MBA8-cSC, respectively, which was loaded on 2-cholorotrityl resin (0.3 g, 0.552 mmol/g) and was swollen in DCM for 20 min, drained as well as washed with

DMF (3 mL, 3x). Coupling of individual amino acids was carried out by using Fmoc-protected amino acids (2 equiv., relative to resin loading) mixed with HATU (2 equiv.) and DIPEA (2 equiv.)

in DMF (5 mL). Coupling reactions were carried out for 1 h with occasional swirling, then washed with DMF (3 mL, 3x). Fmoc-deprotection was done using 20% piperidine in DMF (3 mL) for 7 min

and repeated twice. The resin was washed with DMF (3 mL, 5x) and then coupled with a subsequent amino acid. Then, ester bonds were formed either between the hydroxyl group on the

_N_-terminal fatty acid or an amino acid-associated hydroxyl group and the _C_-terminal carboxyl group of the peptide. The resin was mixed with amino acid (20 equiv.), DIPEA (40 equiv.),

benzoyl chloride (20 equiv.), and DMAP (0.8 equiv.) in 10 mL DCM and gently shaken for 72–96 h. After the ester bond formation, the remaining amino acids were coupled as described above.

Furthermore, peptides were cleaved from the resin by treatment with 20% HFIP in DCM for 2 h. After air drying overnight, the cleaved linear peptide was cyclized without purification using

PyAOP (8 equiv.) and DIPEA (30 equiv.) in DMF (50 mL). After 2 h, DCM (100 mL) was added and washed repeatedly with 1% (v/v) formic acid in water (5 mL, 10x). The extracted cyclic peptide

was air-dried overnight. Finally, air-dried cyclic peptide was dissolved in 3 mL cleavage cocktail (95% (v/v) TFA, 2.5% (v/v) triisopropylsilane and 2.5% (v/v) H2O) for 1.5 h. A cold mixture

of diethyl ether:hexane (1:1) was then added and kept at −20 °C for 10 min to precipitate the peptide. Peptide pellets were harvested by centrifuging (2500×_g_) for 5 min, re-dissolved in 5

 mL methanol, and dried under vacuum overnight. PEPTIDE PURIFICATION AND IDENTIFICATION Crude MBA7-cFA, MBA7-cSC, MBA8-cFA, and MBA8-cSC peptides were purified on an Xbridge Prep C18 HPLC

column using a dual solvent system (A/B: water/acetonitrile). All peptides were eluted using a linear gradient from 20 to 50% gradient of B. The identities of purified MBA7-cFA, MBA7-cSC,

MBA8-cFA, and MBA8-cSC were confirmed by HPLC and HRMS. Finally, 1H, 13C, DEPT135°, COSY, HSQC, and HMBC NMR spectra were recorded for both silvmeb and pseudomeb. ANTIMICROBIAL ASSAYS

AGAINST GRAM-POSITIVE BACTERIA, GRAM-NEGATIVE BACTERIA, AND YEAST PATHOGENS All antimicrobial assays were run in 96-well microtiter plates using a broth micro-dilution method14. Overnight

cultures were diluted 1000- and 10,000-fold in LB broth for _Enterococcus faecalis_ and _S. aureus_, respectively. For yeast strains, overnight cultures were diluted 2000-fold in YPD broth.

For other bacteria, overnight cultures were diluted 5000-fold in LB broth. About 100 µL of each diluted culture was mixed with 100 μL of LB broth containing each peptide at twofold serial

dilutions across a 96-well microtiter plate row. The final concentration of each compound ranged from 64 to 0.125 μg/mL. Plates were incubated at 37 °C (bacteria) or 30 °C (yeast) for 16 h.

The lowest concentration that inhibited visible microbial growth was recorded as the minimum inhibition concentration (MIC). All MIC assays were done in duplicate (_n_ = 2). ANTIBACTERIAL

ASSAY AGAINST _MYCOBACTERIUM SMEGMATIS_ MC2 155 _M. smegmatis_ mc2 155 was shaken (200 rpm) at 37 °C for 48 h in 7H9 broth with 0.2% glucose, 0.2% glycerol, and 0.05% tyloxapol. Then, the

bacterial culture was diluted to an OD600 of 0.005, and 100 μL was added to 100 μL of 7H9 broth containing each peptide at twofold serial dilutions. The final concentration of each compound

ranged from 64 to 0.125 μg/mL. All MIC assays were done in duplicate (_n_ = 2). CYTOTOXICITY ASSESSMENT Hela (ATCC, CCL-2) and H295R (ATCC, CRL-2128) human cell lines were grown at 37 °C in

a 5% CO2 atmosphere in Dulbecco’s modified Eagle medium (DMEM). Hela or H295R cells were seeded into 96-well flat-bottom microtiter plates and incubated in DMEM at 37 °C for 24 h. The DMEM

medium was removed by aspiration and replaced with 100 μL of fresh DMEM medium containing each antibiotic at ten serially diluted concentrations ranging from 64 to 0.125 μg/mL. After 48 h at

37 °C, 10 μL of a CCK-8 solution was added to each well. After 2 h at 37 °C, the absorbance at 450 nm for each well was detected for measuring the cytotoxicity of each synthetic peptide

using a microplate reader. Taxol and DMSO were used as the positive and negative controls for the measurement of IC50 of each synthetic peptide against HeLa or H295R, respectively. MEMBRANE

DEPOLARIZATION Membrane depolarization assays were done in 384-well black microtiter plates14. An overnight culture of _S. aureus_ USA300 was collected by centrifugation and resuspended in

PBS to give an OD600 of 0.5. About 100 μL of this cell suspension and 20 μM DiSC3(5) (50 μL) were added to 300 μL of PBS, and then incubated in the dark at room temperature for 15 min. KCl

(2 M, 50 μL) was then added and incubated for another 15 min. The fluorescence intensity of the mixture was recorded continually at 2 s intervals (Ex/Em 643/675 nm). When the signal

stabilized the appropriate amount of silvmeb or pesudomeb (6.4 mg/mL DMSO stock solutions) to give 2x its MIC was added and immediately mixed by manual pipetting. Vancomycin and gramicidin

were used as the negative and positive controls, respectively. Data were presented as the relative intensity with respect to the average fluorescence signal prior to the addition of silvmeb

or pseudomeb. All assays were done in duplicate (_n_ = 2). SILVMEB OR PSEUDOMEB RESISTANT MUTANT SELECTION14 A single _S. aureus_ USA300 colony was picked into LB medium and grown at 37 °C

overnight. Then, a portion of the overnight culture containing 109 cells was diluted (1/100x or 1/40x) into LB containing silvmeb or pseudomeb at 4x its MIC. The mixtures were distributed

into microtiter plates at 10 μL per well. After incubating at 37 °C overnight, appeared colonies were transferred into an LB medium. The MICs of three to five individual colonies were

determined. Then, genomic DNA was extracted from cultures of colonies that showed an elevated MIC relative to the wildtype. Finally, single-nucleotide polymorphisms (SNPs) for silvmeb or

pseudomeb were identified by mapping genomic DNA sequencing reads to the reference genome of _S. aureus_ USA300. MOUSE PERITONITIS-SEPSIS MODEL Six-week-old female ICR mice were used in all

experiments14. The housing room for mice was on a twelve-hour light cycle with a temperature of 20 °C and a relative humidity of 30%. _S. aureus_ USA300 was cultured in LB Broth at 37 °C

overnight and diluted with 7% type II porcine stomach mucin with 0.2 mM FeNH4-citrate. Cultures were diluted to provide a challenge inoculum of 2.5 × 108 CFU in 0.5 mL. About 0.2 mL of the

challenge inoculum was administered via intraperitoneal injection. 25 mice were randomly grouped into five per cohort (_n_ = 5), and each cohort was given a single dose of either vehicle

(30% solutol), silvmeb, or pesudomeb at 10, 25, or 50 mg/kg and vancomycin at 50 mg/kg 1 h after infection via subcutaneous injection. Mice were observed twice daily for mortality and

morbidity and for possible signs of acute toxicity. Abnormal clinical signs were recorded if observed. ETHICS STATEMENT Shanghai Public Health Clinical Center Animal Care and Use Committee

approved all animal procedures under the protocol 2024-A002-02. We have complied with all relevant ethical regulations for animal use. STATISTICS AND REPRODUCIBILITY Unless stated otherwise,

three independent biological replicates (_n_ = 3) were used for each experiment. No data were excluded from the analyses and data were shown as mean values ± s.e.m. No specific statistical

method was used to predetermine sample size. Besides the mouse experiments, other experiments were not randomized. DATA AVAILABILITY The data underlying this study are available in the

published article and its Supplemental Information. The MBA7 (silvmeb) BGC from _D. silvatica_ GDMCC 1.1900, the potential MBA1 BGC from _E. terrae_ P9846-PB, the MBA8 BGC from _L. capsici_

NF87-2 and the MBA8 (pseudomeb) BGC from _Pseudomonas_ sp. CGJS7 have been deposited in the NCBI database under the deposition numbers PP372680, PP372681, PP768666, and PP768667,

respectively. The source data behind the graphs in the paper can be found in Supplementary Data 1–2. REFERENCES * GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated

with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. _Lancet_ 400, 2221–2248 (2022). Article  Google Scholar  * Tacconelli, E. et al.

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. _Lancet Infect. Dis._ 18, 318–327 (2018). Article  PubMed 

Google Scholar  * Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. _Nature_ 529, 336–343 (2016). Article  CAS  PubMed  Google Scholar  * Lewis, K. The

science of antibiotic discovery. _Cell_ 181, 29–45 (2020). Article  CAS  PubMed  Google Scholar  * Cook, M. A. & Wright, G. D. The past, present, and future of antibiotics. _Sci. Transl.

Med._ 14, eabo7793 (2022). Article  CAS  PubMed  Google Scholar  * Johnston, J. M. & Bulloch, E. M. Advances in menaquinone biosynthesis: sublocalisation and allosteric regulation.

_Curr. Opin. Struct. Biol._ 65, 33–41 (2020). Article  CAS  PubMed  Google Scholar  * Boersch, M., Rudrawar, S., Grant, G. & Zunk, M. Menaquinone biosynthesis inhibition: a review of

advancements toward a new antibiotic mechanism. _RSC Adv._ 8, 5099–5105 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Paudel, A., Hamamoto, H., Panthee, S. & Sekimizu,

K. Menaquinone as a potential target of antibacterial agents. _Drug Discov. Ther._ 10, 123–128 (2016). Article  CAS  PubMed  Google Scholar  * Hamamoto, H. et al. Lysocin E is a new

antibiotic that targets menaquinone in the bacterial membrane. _Nat. Chem. Biol._ 11, 127–133 (2015). Article  CAS  PubMed  Google Scholar  * Kato, A. et al. A new anti-MRSA antibiotic

complex, WAP-8294A. I. Taxonomy, isolation and biological activities. _J. Antibiot._ 51, 929–935 (1998). Article  CAS  Google Scholar  * Itoh, H. et al. Total synthesis and biological mode

of action of WAP-8294A2: a menaquinone-targeting antibiotic. _J. Org. Chem._ 83, 6924–6935 (2018). Article  CAS  PubMed  Google Scholar  * Sang, M. et al. Identification of an anti-MRSA

cyclic lipodepsipeptide, WBP-29479A1, by genome mining of _Lysobacter antibioticus_. _Org. Lett._ 21, 6432–6436 (2019). Article  CAS  PubMed  Google Scholar  * Butler, M. S., Blaskovich, M.

A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. _J. Antibiot._ 66, 571–591 (2013). Article  CAS  Google Scholar  * Li, L. et al. Identification of structurally diverse

menaquinone-binding antibiotics with in vivo activity against multidrug-resistant pathogens. _Nat. Microbiol._ 7, 120–131 (2022). Article  CAS  PubMed  Google Scholar  * Chu, J. et al.

Discovery of MRSA active antibiotics using primary sequence from the human microbiome. _Nat. Chem. Biol._ 12, 1004–1006 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Chu,

J., Vila-Farres, X. & Brady, S. F. Bioactive synthetic-bioinformatic natural product cyclic peptides inspired by nonribosomal peptide synthetase gene clusters from the human microbiome.

_J. Am. Chem. Soc._ 141, 15737–15741 (2019). Article  CAS  PubMed  PubMed Central  Google Scholar  * Wang, Z., Koirala, B., Hernandez, Y., Zimmerman, M. & Brady, S. F. Bioinformatic

prospecting and synthesis of a bifunctional lipopeptide antibiotic that evades resistance. _Science_ 376, 991–996 (2022). Article  CAS  PubMed  PubMed Central  Google Scholar  * Masschelein,

J., Jenner, M. & Challis, G. L. Antibiotics from Gram-negative bacteria: a comprehensive overview and selected biosynthetic highlights. _Nat. Prod. Rep._ 34, 712–783 (2017). Article 

CAS  PubMed  Google Scholar  * Li, L. Accessing hidden microbial biosynthetic potential from underexplored sources for novel drug discovery. _Biotechnol. Adv._ 66, 108176 (2023). Article 

CAS  PubMed  Google Scholar  * Brinkmann, S., Spohn, M. S. & Schäberle, T. F. Bioactive natural products from Bacteroidetes. _Nat. Prod. Rep._ 39, 1045–1065 (2022). Article  CAS  PubMed

  Google Scholar  * Blin, K. et al. antiSMASH 7.0: new and improved predictions for detection, regulation, chemical structures and visualisation. _Nucleic Acids Res._ 51, W46–W50 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar  * Stachelhaus, T., Mootz, H. D. & Marahiel, M. A. The specificity-conferring code of adenylation domains in nonribosomal peptide

synthetases. _Chem. Biol._ 6, 493–505 (1999). Article  CAS  PubMed  Google Scholar  * Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. _Nature_ 517, 455–459

(2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Feng G. D., _et al_ _Dyella humicola_ sp. nov., _Dyella subtropica_ sp. nov., _Dyella silvatica_ sp. nov. and _Dyella silvae_

sp. nov., isolated from subtropical forest soil. _Int. J. Syst. Evol. Microbiol._ https://doi.org/10.1099/ijsem.0.005878 (2023). * Bionda, N., Pitteloud, J. P. & Cudic, P. Cyclic

lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria. _Future Med. Chem._ 5, 1311–1330 (2013). Article  CAS  PubMed  Google Scholar  * Huycke, M.

M. et al. Extracellular superoxide production by _Enterococcus faecalis_ requires demethylmenaquinone and is attenuated by functional terminal quinol oxidases. _Mol. Microbiol._ 42, 729–740

(2001). Article  CAS  PubMed  Google Scholar  * Collins, M. D. & Jones, D. The distribution of isoprenoid quinones in streptococci of serological groups D and N. _J. Gen. Microbiol._

114, 27–33 (1979). Article  CAS  PubMed  Google Scholar  * Liu, Y., Ding, S., Shen, J. & Zhu, K. Nonribosomal antibacterial peptides that target multidrug-resistant bacteria. _Nat. Prod.

Rep._ 36, 573–592 (2019). Article  CAS  PubMed  Google Scholar  * Kumar, G. & Engle, K. Natural products acting against _S. aureus_ through membrane and cell wall disruption. _Nat.

Prod. Rep._ 40, 1608–164 (2023). Article  CAS  PubMed  Google Scholar  * Laufer, B., Chatterjee, J., Frank, A. O. & Kessler, H. Can _N_-methylated amino acids serve as substitutes for

prolines in conformational design of cyclic pentapeptides? _J. Pept. Sci._ 15, 141–146 (2009). Article  CAS  PubMed  Google Scholar  * Muttenthaler, M., King, G. F., Adams, D. J. &

Alewood, P. F. Trends in peptide drug discovery. _Nat. Rev. Drug Discov._ 20, 309–325 (2021). Article  CAS  PubMed  Google Scholar  * Zong, Y. et al. Gram-scale total synthesis of

teixobactin promoting binding mode study and discovery of more potent antibiotics. _Nat. Commun._ 10, 3268 (2019). Article  PubMed  PubMed Central  Google Scholar  Download references

ACKNOWLEDGEMENTS We thank Prof. Jianming Zhang and Xiaowen Wang at Shanghai Jiao Tong University for cytotoxicity assessment. This work was supported by the National Key Research and

Development Program of China (2023YFA0914200 and 2023YFA0916200), the National Natural Science Foundation of China (32370070), and the Shanghai Municipal Science and Technology Major

Project. AUTHOR INFORMATION Author notes * These authors contributed equally: Runze Sun, Di Zhao, Xuchang Yu. AUTHORS AND AFFILIATIONS * State Key Laboratory of Microbial Metabolism and

School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Rd., Shanghai, 200240, China Runze Sun, Di Zhao, Xuchang Yu, Fei Zhang, Ruixiang You & Lei Li *

State Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, 130 Meilong Rd., Shanghai, 200237, China Xuchang Yu * College of

Life Science, Tarim University, E1487 Tarim Avenue, Alar, 43300, China Fei Zhang & Xiaoxia Luo Authors * Runze Sun View author publications You can also search for this author inPubMed 

Google Scholar * Di Zhao View author publications You can also search for this author inPubMed Google Scholar * Xuchang Yu View author publications You can also search for this author

inPubMed Google Scholar * Fei Zhang View author publications You can also search for this author inPubMed Google Scholar * Ruixiang You View author publications You can also search for this

author inPubMed Google Scholar * Xiaoxia Luo View author publications You can also search for this author inPubMed Google Scholar * Lei Li View author publications You can also search for

this author inPubMed Google Scholar CONTRIBUTIONS R.S., D.Z., and X.Y. contributed equally to this work. R.S., D.Z., X.Y., and L.L. performed all the experiments on peptide synthesis,

bioactivity, and MOA studies. F.Z., R.Y., and L.L. performed the experiment on the animal model. X.L. performed the bioinformatics analysis of MBA BGCs. L.L. provided the funding. L.L.

designed the overall experimental plan, analyzed the experimental raw data, and wrote the manuscript. All authors approved the final submission. CORRESPONDING AUTHOR Correspondence to Lei

Li. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. PEER REVIEW PEER REVIEW INFORMATION _Communications Biology_ thanks Kazuhisa Sekimizu and the other,

anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Christina Karlsson Rosenthal. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature

remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTAL INFORMATION DESCRIPTION OF ADDITIONAL

SUPPLEMENTARY FILES SUPPLEMENTARY DATA 1 SUPPLEMENTARY DATA 2 RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0

International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)

and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material

derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a

credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted

use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Sun, R., Zhao, D., Yu, X. _et al._ Discovery of a family of menaquinone-targeting cyclic lipodepsipeptides for multidrug-resistant Gram-positive

pathogens. _Commun Biol_ 7, 1453 (2024). https://doi.org/10.1038/s42003-024-07159-5 Download citation * Received: 24 July 2024 * Accepted: 28 October 2024 * Published: 07 November 2024 *

DOI: https://doi.org/10.1038/s42003-024-07159-5 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is

not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative